2 research outputs found
Coronary Vulnerability
This thesis aims to improve risk stratification of patients with coronary artery disease. Parts 1 and 2, respectively known as âVulnerable Bloodâ and âVulnerable Periodâ aimed at elucidating the role of various serum biomarkers, and repeated measurements thereof, in order to identify patients at increased risk of myocardial infarction, and more specifically to identify the specific timeframe of that increased risk.
Part 3, âVulnerable Plaqueâ is focused on invasive coronary imaging (coronary angiography, intravascular ultrasound and near-infrared spectroscopy) and the detection of prognostic plaque characteristics, as well as the relation between plaque components and serum biomarkers.
Part 4 âIntervention Studiesâ describes the search for those patient subsets to derive most benefit from current (pharmacologic) interventions in coronary artery disease
The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease
Background
Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure.
Methods
We recruited patients from October, 1997, to June, 2000. 13â655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12â218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4¡2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat.
Findings
Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% β blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% Cl 9â29, p=0¡0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated.
Interpretation
Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease